Ionis Pharmaceuticals Company Profile (NASDAQ:IONS)

Ionis Pharmaceuticals trades on the NASDAQ under the ticker symbol "IONS."

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) issued its quarterly earnings data on Tuesday, August, 8th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.06) by $0.03. The firm earned $104.15 million during the quarter, compared to analysts' expectations of $93.29 million. Ionis Pharmaceuticals had a return on equity of 15.52% and a net margin of 5.25%. The firm's quarterly revenue was up 170.7% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.47) EPS. View Ionis Pharmaceuticals' Earnings History.

Ionis Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, November, 7th 2017. View Earnings Estimates for Ionis Pharmaceuticals.

14 equities research analysts have issued 1-year price targets for Ionis Pharmaceuticals' stock. Their forecasts range from $18.00 to $69.00. On average, they anticipate Ionis Pharmaceuticals' stock price to reach $49.62 in the next year. View Analyst Ratings for Ionis Pharmaceuticals.

Here are some recent quotes from research analysts about Ionis Pharmaceuticals stock:

• 1. According to Zacks Investment Research, "Ionis Pharmaceuticals, Inc. is a RNA-targeted drug discovery and development company which focuses on developing drugs for severe and rare diseases. Ionis Pharmaceuticals, Inc., formerly known as Isis Pharmaceuticals, Inc., is headquartered in Carlsbad, California. " (10/17/2017)
• 2. BMO Capital Markets analysts commented, " We maintain our Outperform rating, but decrease our price target to $59 from $63, following Phase III volanesorsen FCS data that showed strong efficacy, but higher frequency of platelet monitoring to maintain treatment. While we believe volanesorsen will be approved, biweekly monitoring and injection site reactions (ISRs) could limit patient adherence to therapy, leading us to decrease our compliance/ persistence rate to 75% from 85%. Our market share assumptions remain unchanged, given the disease burden and limited treatment options. We estimate Volanesorsen WW peak sales of $820 million." (3/7/2017)
• 3. Needham & Company LLC analysts commented, "Akcea, a wholly owned subsidiary of Ionis Pharmaceuticals, reported that volanesorsen met its primary endpoint of triglyceride lowering in the Phase III APPROACH study in patients with familial chylomicronemia syndrome (FCS). A surprise positive, the study also demonstrated significant reductions in pancreatic attacks and abdominal pain. However, IONS shares are reacting negatively this morning because of the reported incidence of discontinuations for thrombocytopenia. We view the sell off as an over reaction considering that the platelet reductions are disease related and rgw study discontinuations stopped occurring after monitoring was implemented. We maintain our Buy rating on IONS." (3/6/2017)
• 4. Cowen and Company analysts commented, "Ionis provided an update on its pipeline of ~40 antisense drug candidates." (1/6/2017)

Ionis Pharmaceuticals saw a drop in short interest in the month of September. As of September 15th, there was short interest totalling 10,235,812 shares, a drop of 11.1% from the August 31st total of 11,514,444 shares. Based on an average daily volume of 948,653 shares, the short-interest ratio is presently 10.8 days. Currently, 8.3% of the company's shares are sold short.

Some companies that are related to Ionis Pharmaceuticals include Alnylam Pharmaceuticals (ALNY), Seattle Genetics (SGEN), Qiagen N.V. (QGEN), Alkermes PLC (ALKS), Icon Plc (ICLR), INC Research Holdings (INCR), Exact Sciences Corporation (EXAS), Charles River Laboratories International (CRL), PRA Health Sciences (PRAH), United Therapeutics Corporation (UTHR), Galapagos NV (GLPG), Puma Biotechnology (PBYI), Bio-Techne Corp (TECH), PAREXEL International Corporation (PRXL), ACADIA Pharmaceuticals (ACAD), FibroGen (FGEN), Nektar Therapeutics (NKTR) and WuXi PharmaTech (Cayman) (WX).

Ionis Pharmaceuticals' management team includes the folowing people:

• Stanley T. Crooke M.D. Ph.D., Chairman of the Board, President, Chief Executive Officer
• Elizabeth L. Hougen, Chief Financial Officer, Senior Vice President - Finance
• B. Lynne Parshall J.D., Chief Operating Officer, Corporate Secretary, Director
• Patrick R. O'Neil Esq., Senior Vice President, Legal, General Counsel, Chief Compliance Officer and Corporate Secretary
• C. Frank Frank Bennett Ph.D., Senior Vice President - Antisense Research
• Richard S. Geary Ph.D., Senior Vice President - Development
• Brett P. Monia Ph.D., Senior Vice President - Drug Discovery and Corporate Development
• Sarah Boyce, Chief Business Officer
• Spencer R. Berthelsen M.D., Independent Director
• Breaux B. Castleman, Independent Director

Ionis Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Sit Investment Associates Inc. (0.02%). Company insiders that own Ionis Pharmaceuticals stock include B Lynne Parshall, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Frederick T Muto, Ionis Pharmaceuticals Inc, Joseph Klein III, Patrick R O'neil, Richard S Geary, Sarah Boyce and Stanley T Crooke. View Institutional Ownership Trends for Ionis Pharmaceuticals.

Ionis Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Sit Investment Associates Inc.. Company insiders that have sold Ionis Pharmaceuticals stock in the last year include B Lynne Parshall, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Patrick R O'neil, Richard S Geary, Sarah Boyce and Stanley T Crooke. View Insider Buying and Selling for Ionis Pharmaceuticals.

Shares of Ionis Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Ionis Pharmaceuticals stock can currently be purchased for approximately $64.39.